Trending NewsTrending NewsNYSE:BMY Bristol Myers Squibb (BMY) Stock Price, News & Analysis $59.34 +2.67 (+4.72%) Closing price 03:59 PM EasternExtended Trading$59.81 +0.46 (+0.78%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Bristol Myers Squibb Stock (NYSE:BMY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Bristol Myers Squibb alerts:Sign Up Key Stats Today's Range$56.58▼$59.3950-Day Range$56.73▼$68.0652-Week Range$42.52▼$68.64Volume14.04 million shsAverage Volume14.53 million shsMarket Capitalization$121.22 billionP/E Ratio8.71Dividend Yield4.25%Price Target$64.88Consensus RatingHold Company Overview Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets. Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors. Its newer and specialized products include Breyanzi, a cell therapy for certain blood cancers; Camzyos, a cardiovascular medicine; and Sotyktu, an immunology treatment. The company also develops investigational therapies through internal research and collaborations. The company traces its history to the formation of Bristol-Myers in 1889 and the founding of the E.R. Squibb & Sons pharmaceutical business in 1858. Bristol-Myers Squibb was created through the 1989 merger of the two companies. Its corporate headquarters are in Princeton, New Jersey. Christopher Boerner has served as chief executive officer since November 2023.AI Generated. May Contain Errors. Read More Bristol Myers Squibb Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks91st Percentile Overall ScoreBMY MarketRank™: 4.555745689085 of 5 starsBristol Myers Squibb scored higher than 91% of companies evaluated by MarketBeat, and ranked 17th out of 873 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.0 / 5Analyst RatingHold Consensus RatingBristol Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.47, and is based on 2 strong buy ratings, 11 buy ratings, 16 hold ratings, and 1 sell rating.Upside/DownsideThe consensus price target for Bristol Myers Squibb is close to its current price, suggesting limited near-term upside or downside.Amount of Analyst CoverageBristol Myers Squibb has been the subject of 25 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Bristol Myers Squibb's stock forecast and price target. Earnings and Valuation2.5 / 5Proj. Earnings Growth-2.39% Earnings GrowthEarnings for Bristol Myers Squibb are expected to decrease by -2.39% in the coming year, from $6.70 to $6.54 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bristol Myers Squibb is 8.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 40.79.Price to Earnings Ratio vs. SectorThe P/E ratio of Bristol Myers Squibb is 8.71, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 195.97.Price to Earnings Growth RatioBristol Myers Squibb has a PEG Ratio of 0.28. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBristol Myers Squibb has a P/B Ratio of 6.53. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Bristol Myers Squibb's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.25% of the float of Bristol Myers Squibb has been sold short.Short Interest Ratio / Days to CoverBristol Myers Squibb has a short interest ratio ("days to cover") of 3.01, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Bristol Myers Squibb has recently increased by 9.24%, indicating that investor sentiment is decreasing significantly. Dividend5.0 / 5Dividend StrengthStrong Dividend LeadershipBristol Myers Squibb is a leading dividend payer. It pays a dividend yield of 4.45%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthBristol Myers Squibb has been increasing its dividend for 17 years.Dividend CoverageThe dividend payout ratio of Bristol Myers Squibb is 55.51%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, Bristol Myers Squibb will have a dividend payout ratio of 38.53% next year. This indicates that Bristol Myers Squibb will be able to sustain or increase its dividend.Read more about Bristol Myers Squibb's dividend. News and Social Media2.9 / 5News Sentiment0.63 News SentimentBristol Myers Squibb has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 68 news articles for Bristol Myers Squibb this week, compared to 9 articles on an average week.Search InterestOnly 45 people have searched for BMY on MarketBeat in the last 30 days. This is a decrease of -6% compared to the previous 30 days.MarketBeat Follows31 people have added Bristol Myers Squibb to their MarketBeat watchlist in the last 30 days. This is an increase of 138% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bristol Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,750.00 in company stock.Percentage Held by Insiders0.05% of the stock of Bristol Myers Squibb is held by insiders.Percentage Held by Institutions76.41% of the stock of Bristol Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bristol Myers Squibb's insider trading history. Receive BMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bristol Myers Squibb and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMY Stock News HeadlinesAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Lemaitre Vascular (LMAT) and Bristol-Myers Squibb (BMY)October 14 at 1:51 PM | theglobeandmail.comBristol Myers Squibb Company (BMY) Is a Trending Stock: Facts to Know Before Betting on ItOctober 14 at 1:51 PM | finance.yahoo.comA letter from Shannon StansberryPorter Stansberry nearly canceled the entire project. When he first saw the claimed returns - only one down year in nearly two decades and total gains of almost 2,000% - his immediate reaction was disbelief. It took a trusted friend's personal vouching for Emmet Savage and a face-to-face trip to Ireland to change his mind. The full documentary, Investigating Project Prophet, is now live.October 14 at 1:00 AM | Porter & Company (Ad)These 4 Dividend Stocks Passed the 2020 Stress Test. Are They Buys in Now October?October 14 at 1:51 PM | 247wallst.comThese 4 Dividend Stocks Passed the 2020 Stress Test. Are They Buys in Now October?October 14 at 1:15 PM | 247wallst.comAnalysts Conflicted on These Healthcare Names: Resmed (RMD) and Bristol-Myers Squibb (BMY)October 14 at 8:50 AM | theglobeandmail.comTruist Financial Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY)October 14 at 8:50 AM | theglobeandmail.comBlockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep PayingOctober 14 at 8:50 AM | 247wallst.comSee More Headlines BMY Stock Analysis - Frequently Asked Questions How have BMY shares performed this year? Bristol Myers Squibb's stock was trading at $53.93 at the beginning of 2026. Since then, BMY stock has increased by 10.0% and is now trading at $59.3440. How were Bristol Myers Squibb's earnings last quarter? Bristol Myers Squibb Company (NYSE:BMY) released its earnings results on Thursday, July, 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.60 by $0.44. The firm's quarterly revenue was up 5.7% on a year-over-year basis. Read the conference call transcript. When did Bristol Myers Squibb's stock split? Bristol Myers Squibb's stock split on the morning of Thursday, June 26th 2014.The 2-1 split was announced on Thursday, June 19th 2014. The newly created shares were payable to shareholders after the closing bell on Wednesday, June 25th 2014. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Bristol Myers Squibb have any subsidiaries? Bristol Myers Squibb subsidiaries include these companies: MyoKardia, Forbius, Celgene, IFM Therapeutics, Cormorant Pharmaceuticals, Padlock Therapeutics, Cardioxyl Pharmaceuticals, and more. Who are Bristol Myers Squibb's major shareholders? Bristol Myers Squibb's top institutional shareholders include Artemis Investment Management LLP (0.14%), Douglas Lane & Associates LLC (0.07%), Mn Services Vermogensbeheer B.V. (0.03%) and NorthCrest Asset Manangement LLC (0.02%). Insiders that own company stock include David V Elkins, Samit Hirawat, Christopher S Boerner, Theodore R Samuels II, Phil M Holzer, Benjamin Hickey and Bartie Wendy Short. View institutional ownership trends. How do I buy shares of Bristol Myers Squibb? Shares of BMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bristol Myers Squibb own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bristol Myers Squibb investors own include NVIDIA (NVDA), Pfizer (PFE), AbbVie (ABBV), Gilead Sciences (GILD), Johnson & Johnson (JNJ), AT&T (T) and Verizon Communications (VZ). Company Calendar Record date for 8/3 Dividend7/02/2026Ex-Dividend for 8/3 Dividend7/02/2026Last Earnings7/30/2026Dividend Payable8/03/2026Record date for 11/2 Dividend10/02/2026Ex-Dividend for 11/2 Dividend10/02/2026Today10/14/2026Next Earnings (Estimated)10/29/2026Dividend Payable11/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2d) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 As of 2 days ago, BMY's financial health entered the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSE SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSE:BMY CIK14272 Webwww.bms.com Phone(609) 252-4621Fax212-546-4020Employees32,500Year Founded1887Price Target and Rating Average Price Target for Bristol Myers Squibb$64.88 High Price Target$76.00 Low Price Target$41.00 Potential Upside/Downside+9.3%Consensus RatingHold Rating Score (0-4)2.47 Research Coverage30 Analysts Profitability EPS (Trailing Twelve Months)$4.54 Trailing P/E Ratio8.71 Forward P/E Ratio8.86 P/E Growth0.28Net Income$7.05 billion Net Margins18.87% Pretax Margin24.21% Return on Equity66.90% Return on Assets14.74% Debt Debt-to-Equity Ratio1.89 Current Ratio1.53 Quick Ratio1.38 Sales & Book Value Annual Sales$48.19 billion Price / Sales2.52 Cash Flow$8.51 per share Price / Cash Flow6.97 Book Value$9.09 per share Price / Book6.53Miscellaneous Outstanding Shares2,042,710,000Free Float2,041,694,000Market Cap$121.22 billion OptionableOptionable Beta0.19 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NYSE:BMY) was last updated on 10/14/2026 by MarketBeat.com Staff. From Our PartnersA new income category is drawing serious money - here's whyForbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the ...Investors Alley | SponsoredDo this before December or regret itPorter Stansberry believes President Trump will use the December G20 Summit in Miami to unveil a radical monet...Porter & Company | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredFederal Reserve Reveals Disturbing New Plan To Control Your MoneyA Federal Reserve filing, Docket No. OP-1670, is drawing scrutiny for language that could expand the Fed's vis...Weiss Ratings | SponsoredTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredElon Musk’s One Stock Retirement PlanJeff Brown picked Nvidia in 2016, before it surged 37,000 percent. Now he's tracking a small AI company he say...Brownstone Research | SponsoredYou’d Never Guess What Their European Chalet CostEric and Debbie, a couple in their 60s from Burbank, California, retired to a private chalet on a European cou...International Living | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bristol Myers Squibb Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Bristol Myers Squibb With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
